Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:RVNC
- CUSIP: N/A
- Web: www.revance.com
Capitalization:- Market Cap: $742.74 million
- Outstanding Shares: 30,819,000
Average Prices:- 50 Day Moving Avg: $23.75
- 200 Day Moving Avg: $22.58
- 52 Week Range: $12.35 - $28.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.85
- P/E Growth: -0.56
Sales & Book Value:- Annual Revenue: $300,000.00
- Price / Sales: 2,475.79
- Book Value: $5.24 per share
- Price / Book: 4.60
Profitability:- EBIDTA: ($89,740,000.00)
- Net Margins: -32,936.67%
- Return on Equity: -55.21%
- Return on Assets: -47.75%
Debt:- Current Ratio: 7.94%
- Quick Ratio: 7.94%
Misc:- Average Volume: 171,227 shs.
- Beta: 1.6
- Short Ratio: 23.45
Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics, Inc. (NASDAQ:RVNC) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.93) by $0.03. The business earned $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The firm's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.88) earnings per share. View Revance Therapeutics' Earnings History.
Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?
4 brokerages have issued 12 month target prices for Revance Therapeutics' shares. Their forecasts range from $28.00 to $50.00. On average, they expect Revance Therapeutics' stock price to reach $37.00 in the next year. View Analyst Ratings for Revance Therapeutics.
What are analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (9/19/2017)
- 2. Cantor Fitzgerald analysts commented, "Today Revance announced that Mark Foley has been appointed to the Board of Directors, effective 9/5/17." (9/6/2017)
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include MyoKardia (MYOK), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Amarin Corporation PLC (AMRN), Retrophin (RTRX), ZIOPHARM Oncology (ZIOP) and REGENXBIO (RGNX).
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Angus Charles Russell, Independent Chairman of the Board
- L. Daniel Browne, Co-Founder, President, Chief Executive Officer, Director
- Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer
- Abhay Joshi Ph.D., Chief Operating Officer
- Todd E. Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics
- Robert F. Byrnes, Independent Director
- Ronald W. Eastman, Independent Director
- Julian S. Gangolli, Independent Director
- Phyllis I. Gardner M.D., Independent Director
- Philip J. Vickers, Independent Director
Who owns Revance Therapeutics stock?
Revance Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (11.98%), Franklin Resources Inc. (11.15%), Bank of New York Mellon Corp (6.87%), Vanguard Group Inc. (3.08%), Canada Pension Plan Investment Board (1.93%) and State Street Corp (1.47%). Company insiders that own Revance Therapeutics stock include Arthur Peter Bertolino, Curtis Ruegg, L Daniel Browne and Lauren P Silvernail. View Institutional Ownership Trends for Revance Therapeutics.
Who sold Revance Therapeutics stock? Who is selling Revance Therapeutics stock?
Revance Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wells Fargo & Company MN, Paradigm Asset Management Co. LLC, TIAA CREF Investment Management LLC, Suffolk Capital Management LLC, Granite Investment Partners LLC, Rothschild Asset Management Inc. and Victory Capital Management Inc.. Company insiders that have sold Revance Therapeutics stock in the last year include L Daniel Browne and Lauren P Silvernail. View Insider Buying and Selling for Revance Therapeutics.
Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?
Revance Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Jennison Associates LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., PointState Capital LP, Vanguard Group Inc., QS Investors LLC and Northern Trust Corp. View Insider Buying and Selling for Revance Therapeutics.
How do I buy Revance Therapeutics stock?
Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of Revance Therapeutics stock can currently be purchased for approximately $24.10.
MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $37.00 (53.53% upside) |
Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/6/2017 | Cantor Fitzgerald | Reiterated Rating | Buy | $50.00 | Low |  |
| 8/22/2017 | JMP Securities | Initiated Coverage | Mkt Outperform -> Outperform | $34.00 | Medium | |
| 7/26/2017 | Piper Jaffray Companies | Set Price Target | Buy | $28.00 | Low | |
| 6/8/2017 | Aegis | Reiterated Rating | Buy | $36.00 | Medium | |
| 8/5/2016 | Brean Capital | Reiterated Rating | Hold | | N/A | |
| 6/14/2016 | SunTrust Banks, Inc. | Lower Price Target | Buy | $46.00 -> $22.00 | N/A | |
| 6/14/2016 | Guggenheim | Reiterated Rating | Buy | $55.00 | N/A | |
| 12/30/2015 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
| 11/10/2015 | William Blair | Reiterated Rating | Buy | $59.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Revance Therapeutics (NASDAQ:RVNC)Earnings History by Quarter for Revance Therapeutics (NASDAQ RVNC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($0.93) | ($0.90) | $0.05 million | $0.08 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.84) | ($0.94) | $0.07 million | $0.08 million | View | Listen | |
| 2/27/2017 | Q416 | ($0.84) | ($0.95) | $0.07 million | $0.08 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.89) | ($0.64) | $0.08 million | $0.08 million | View | N/A | |
| 8/4/2016 | Q216 | ($0.86) | ($0.88) | $0.06 million | $0.80 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.83) | ($0.71) | $0.08 million | $0.08 million | View | Listen | |
| 3/2/2016 | Q415 | ($0.86) | ($0.83) | $0.09 million | $0.08 million | View | Listen | |
| 11/9/2015 | Q315 | ($1.01) | ($0.81) | $0.10 million | $0.08 million | View | N/A | |
| 8/6/2015 | Q415 | ($0.84) | ($0.71) | $0.15 million | $0.08 million | View | N/A | |
| 5/13/2015 | Q1 | ($0.69) | ($0.65) | $0.15 million | $0.08 million | View | Listen | |
| 3/2/2015 | | ($0.53) | ($0.60) | $0.08 million | $0.08 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.69) | ($0.60) | | $0.08 million | View | N/A | |
| 8/12/2014 | | ($0.68) | ($0.69) | | $0.08 million | View | N/A | |
| 5/13/2014 | Q1 14 | ($0.87) | ($1.93) | | $0.16 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)2017 EPS Consensus Estimate: ($3.80)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.85) | ($0.80) | ($0.83) |
| Q2 2017 | 2 | ($0.99) | ($0.98) | ($0.99) |
| Q3 2017 | 2 | ($1.02) | ($1.02) | ($1.02) |
| Q4 2017 | 2 | ($0.99) | ($0.95) | ($0.97) |
(Data provided by Zacks Investment Research)
Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ:RVNC)Insider Ownership Percentage: 18.86%
Institutional Ownership Percentage: 89.32%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/20/2017 | L Daniel Browne | CEO | Sell | 7,600 | $23.58 | $179,208.00 | |
| 8/23/2017 | L Daniel Browne | CEO | Sell | 22,800 | $22.76 | $518,928.00 | |
| 5/24/2017 | L Daniel Browne | CEO | Sell | 19,713 | $20.35 | $401,159.55 | |
| 5/22/2017 | L Daniel Browne | CEO | Sell | 12,287 | $20.20 | $248,197.40 | |
| 5/22/2017 | Lauren P Silvernail | CFO | Sell | 1,793 | $20.20 | $36,218.60 | |
| 1/25/2017 | L Daniel Browne | CEO | Sell | 12,000 | $19.78 | $237,360.00 | |
| 12/28/2016 | L Daniel Browne | CEO | Sell | 12,000 | $20.94 | $251,280.00 | |
| 11/25/2016 | L Daniel Browne | CEO | Sell | 12,000 | $17.92 | $215,040.00 | |
| 10/26/2016 | L Daniel Browne | CEO | Sell | 12,000 | $14.85 | $178,200.00 | |
| 6/13/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $18.25 | $18,250.00 | |
| 5/9/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $16.18 | $16,180.00 | |
| 4/11/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $19.11 | $19,110.00 | |
| 3/7/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $20.43 | $20,430.00 | |
| 2/8/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $18.14 | $18,140.00 | |
| 1/6/2016 | Curtis Ruegg | EVP | Sell | 2,000 | $33.06 | $66,120.00 | |
| 11/17/2015 | Arthur Peter Bertolino | EVP | Sell | 7,753 | $39.11 | $303,219.83 | |
| 8/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $30.33 | $90,990.00 | |
| 7/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $31.03 | $93,090.00 | |
| 6/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $33.53 | $100,590.00 | |
| 5/18/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $26.42 | $79,260.00 | |
| 4/17/2015 | Curtis Ruegg | EVP | Sell | 2,000 | $22.23 | $44,460.00 | |
| 3/17/2015 | Curtis Ruegg | EVP | Sell | 1,500 | $18.61 | $27,915.00 | |
| 3/9/2015 | Curtis Ruegg | EVP | Sell | 500 | $18.00 | $9,000.00 | |
| 2/17/2015 | Curtis Ruegg | EVP | Sell | 1,000 | $16.80 | $16,800.00 | |
| 1/20/2015 | Curtis Ruegg | EVP | Sell | 1,000 | $17.25 | $17,250.00 | |
| 12/17/2014 | Curtis Ruegg | EVP | Sell | 1,000 | $16.45 | $16,450.00 | |
| 11/28/2014 | L Daniel Browne | CEO | Buy | 6,000 | $16.67 | $100,020.00 | |
| 11/18/2014 | Curtis Ruegg | EVP | Sell | 1,000 | $16.00 | $16,000.00 | |
| 9/17/2014 | Curtis Ruegg | EVP | Sell | 2,000 | $20.55 | $41,100.00 | |
| 9/17/2014 | Jacob Waugh | Insider | Sell | 97,713 | $20.73 | $2,025,590.49 | |
(Data available from 1/1/2013 forward)
Headline Trends for Revance Therapeutics (NASDAQ:RVNC)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
| Source: |
|
| Date | Headline |
|---|
 | Revance Therapeutics, Inc. (RVNC) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - September 24 at 1:32 PM |
| Revance Therapeutics, Inc. (RVNC) CEO Sells $179,208.00 in Stock
www.americanbankingnews.com - September 22 at 10:32 PM |
 | Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference
finance.yahoo.com - September 20 at 8:34 AM |
| ETFs with exposure to Revance Therapeutics, Inc. : September 19, 2017
finance.yahoo.com - September 20 at 8:34 AM |
| Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 7:22 AM |
| Zacks Investment Research Lowers Revance Therapeutics, Inc. (RVNC) to Hold
www.americanbankingnews.com - September 16 at 12:24 PM |
| Zacks Investment Research Upgrades Revance Therapeutics, Inc. (RVNC) to "Buy"
www.americanbankingnews.com - September 9 at 6:22 PM |
| Revance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 8 at 2:44 AM |
| Revance Therapeutics, Inc. (RVNC) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 7 at 8:20 AM |
| Cantor Fitzgerald Reaffirms Buy Rating for Revance Therapeutics, Inc. (RVNC)
www.americanbankingnews.com - September 6 at 1:28 PM |
| Revance Appoints Mark Foley to its Board of Directors
finance.yahoo.com - September 6 at 7:51 AM |
| Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 1, 2017
finance.yahoo.com - September 2 at 8:17 AM |
| Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
finance.yahoo.com - August 31 at 9:38 AM |
| Revance Therapeutics, Inc. (RVNC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 30 at 6:28 AM |
| Revance Therapeutics, Inc. (RVNC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 27 at 12:28 AM |
| Revance Therapeutics, Inc. (RVNC) CEO L Daniel Browne Sells 22,800 Shares
www.americanbankingnews.com - August 25 at 10:28 PM |
| $80,000.00 in Sales Expected for Revance Therapeutics, Inc. (RVNC) This Quarter
www.americanbankingnews.com - August 25 at 7:48 AM |
| Revance Therapeutics, Inc. (RVNC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 22 at 11:22 AM |
| JMP Securities Initiates Coverage on Revance Therapeutics, Inc. (RVNC)
www.americanbankingnews.com - August 22 at 9:08 AM |
| BidaskClub Upgrades Revance Therapeutics, Inc. (RVNC) to "Hold"
www.americanbankingnews.com - August 18 at 7:35 PM |
 | Revance Therapeutics: An Undervalued Botox Competitor
seekingalpha.com - August 17 at 4:17 PM |
| Revance Therapeutics, Inc. (RVNC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 15 at 9:56 AM |
| Revance Therapeutics, Inc. (RVNC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 14 at 2:44 AM |
| Zacks Investment Research Lowers Revance Therapeutics Inc (NASDAQ:RVNC) to Hold
www.americanbankingnews.com - August 12 at 5:08 PM |
| FY2017 Earnings Forecast for Revance Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:RVNC)
www.americanbankingnews.com - August 10 at 9:32 AM |
| Revance Therapeutics, Inc. (NASDAQ:RVNC) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 5 at 5:08 PM |
| Edited Transcript of RVNC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 5 at 6:46 AM |
| Revance Releases Second Quarter 2017 Results
finance.yahoo.com - August 4 at 7:50 AM |
| Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : July 31, 2017
finance.yahoo.com - August 1 at 6:09 AM |
| Brokers Offer Predictions for Revance Therapeutics, Inc.'s FY2017 Earnings (NASDAQ:RVNC)
www.americanbankingnews.com - July 26 at 11:16 AM |
| Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017
finance.yahoo.com - July 25 at 6:22 AM |
| Revance Therapeutics, Inc. (RVNC) Now Covered by Cantor Fitzgerald
www.americanbankingnews.com - July 20 at 7:08 PM |
| Revance Therapeutics, Inc. (RVNC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 20 at 6:26 PM |
| Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : July 17, 2017
finance.yahoo.com - July 17 at 3:35 PM |
 | Commit To Purchase Revance Therapeutics At $20, Earn 11.6% Annualized Using Options
www.nasdaq.com - July 8 at 7:11 PM |
| Revance Therapeutics, Inc. (NASDAQ:RVNC) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - July 6 at 7:50 PM |
| Brokers Set Expectations for Revance Therapeutics, Inc.'s FY2017 Earnings (RVNC)
www.americanbankingnews.com - June 19 at 7:20 AM |
| Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery
finance.yahoo.com - June 16 at 9:33 AM |
| Revance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - June 13 at 6:26 PM |
| Revance Therapeutics Inc (RVNC) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 9 at 3:22 PM |
| Revance Therapeutics Inc (RVNC) Earns Buy Rating from Aegis
www.americanbankingnews.com - June 8 at 9:02 AM |
 | Revance Therapeutics (RVNC) Reports Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
www.streetinsider.com - June 6 at 9:57 PM |
| Revance Therapeutics (RVNC) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 6 at 9:57 PM |
| Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
finance.yahoo.com - June 5 at 9:41 PM |
| Revance Therapeutics Inc (RVNC) Short Interest Up 4.0% in May
www.americanbankingnews.com - May 31 at 8:44 AM |
| Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : May 26, 2017
finance.yahoo.com - May 27 at 4:06 AM |
| Revance Therapeutics Inc (RVNC) CEO L Daniel Browne Sells 19,713 Shares
www.americanbankingnews.com - May 24 at 10:57 PM |
| Revance Therapeutics Inc (RVNC) CFO Lauren P. Silvernail Sells 1,793 Shares
www.americanbankingnews.com - May 24 at 10:56 PM |
| Revance Therapeutics Inc (RVNC) CEO Sells $248,197.40 in Stock
www.americanbankingnews.com - May 24 at 10:56 PM |
| Revance Therapeutics (RVNC) Presents On Phase 2 Cervical Dystonia 24-Week Results - Slideshow
seekingalpha.com - May 23 at 7:01 PM |
Revance Therapeutics (RVNC) Chart for Sunday, September, 24, 2017
